Percentage of total mortality cases from CHD, CVD, and other causes (A). Percentage of total mortality cases from CHD, CVD, and other causes (A). Mortality.

Slides:



Advertisements
Similar presentations
Lipid Profiles & NSW LCDR Jim Mucciarone NSWG-2 16 July 2008.
Advertisements

Fat or Low-fat? Anwar T. Merchant ScD, MPH, DMD Department of Epidemiology and Biostatistics.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Efficacy of Omeprazole for the Treatment of Symptomatic.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Use of Inhaled Corticosteroids and the Risk.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effects of Habitual Coffee Consumption on Cardiometabolic.
Date of download: 6/25/2016 Copyright © 2016 American Medical Association. All rights reserved. From: The Colorado Thyroid Disease Prevalence Study Arch.
Date of download: 6/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Cardiorespiratory Fitness as a Quantitative Predictor.
Date of download: 7/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Variation in Use of Dual-Chamber Implantable Cardioverter-Defibrillators:
Date of download: 7/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Reference Payment for Colonoscopy.
Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association Between Endoscopic vs Open Vein-Graft.
From: Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study Ann Intern Med. 2015;163(5):
Copyright © 2008 Vista Higher Learning. All rights reserved. 9.
Copyright © 2005 American Medical Association. All rights reserved.
Copyright © 2005 American Medical Association. All rights reserved.
Copyright © 2011 American Medical Association. All rights reserved.
Copyright © 2005 American Medical Association. All rights reserved.
Ann Intern Med. 2014;160(11): doi: /M Figure Legend:
Definitions of the MetS by the WHO, EGIR, NCEP, ACE, IDF, and updated NCEP criteria Wang J, et al. Eur Heart J 2007;28:
Copyright © 2011 American Medical Association. All rights reserved.
Copyright © 2006 American Medical Association. All rights reserved.
Copyright © 2014 American Medical Association. All rights reserved.
Copyright © 2000 American Medical Association. All rights reserved.
Copyright © 2008 American Medical Association. All rights reserved.
Copyright © 2004 American Medical Association. All rights reserved.
Copyright © 2011 American Medical Association. All rights reserved.
Risk stratification using gated stress myocardial perfusion imaging: comparison between patients with and without sexual dysfunction by Yusuf Ziya Tan,
Copyright © 2002 American Medical Association. All rights reserved.
Copyright © 2001 American Medical Association. All rights reserved.
Copyright © 2007 American Medical Association. All rights reserved.
Copyright © 2004 American Medical Association. All rights reserved.
Copyright © 2012 American Medical Association. All rights reserved.
CYB561 mutations. CYB561 mutations. The upper part shows the structure of the CYB561 gene, with the positions of the identified mutations indicated. Gray.
Behavior and Biology: The Basic Sciences for AHA Action
Influence of Cardiac Surgeon Report Cards on Patient Referral by Cardiologists in New York State After 20 Years of Public Reporting by David L. Brown,
Association between highest tertile for homocysteine and mortality
Fung TT, et al. Circulation 2009;119:
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
David J.A. Jenkins et al. JACC 2018;71:
Effect of confidence interval reduction to demonstrate a true difference in means. Effect of confidence interval reduction to demonstrate a true difference.
Methods distribution among the three EQAs
Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,
Patient characteristics: American vs Canadian transplant patients
P. Michael Grossman et al. JCIN 2009;2:
Pamela E. Scott et al. JACC 2018;71:
Decline in the risk of carotid occlusion with more intensive medical therapy. Decline in the risk of carotid occlusion with more intensive medical therapy.
Patients’ most feared AEs reported to be intolerable when lasting more than 7 days at baseline, on study and at study completion (% patients); (A) grade.
Risk of having any adverse effects with supplements compared with placebo. Risk of having any adverse effects with supplements compared with placebo. Stratified.
Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.
Relationship between selected metabolic parameters and the primary composite end point. Relationship between selected metabolic parameters and the primary.
Concentration-time profiles of repeated weekly infusions of (A) 720 mg and (B) 990 mg tomuzotuximab measured in individual patients before and at the end.
Computed tomography (CT) of head without contrast revealed cerebral atrophy, air in left cavernous sinus, right transverse foramen on C1 (A) which tracked.
Fig. 7 Bacterial dependency networks in IgA deficiency and HDs.
Increase in adults treated at children's hospitals, 1999–2012, according to age group and disease. Increase in adults treated at children's hospitals,
(A) There was a 3–4 mm ventriculospetal defect at the base of the heart inferiorly, slightly anterior to the coronary sinus, (B) Adjacent to this VSD,
Multivariate-adjusted HRs (95% CI) for deaths from CV disease (CVD), coronary heart disease (CHD), stroke, and all-cause mortality according to fasting.
Meta-analysis of risk ratios for percentage of patients who developed catheter-associated urinary tract infection, for intervention versus control groups,
Flowchart of the process of study selection LAR indicates laboratory-defined aspirin resistance Jaapjan D. Snoep, et al. Arch Intern Med 2007;167:
Meta-analysis of risk ratios for percentage of patients who developed catheter-associated urinary tract infection, for intervention versus control groups,
Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.
Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.
Kaplan-Meir survival plots for CHD mortality (A), CVD mortality (B), and all-cause mortality (C) in men grouped by TG/HDL-C ratio of 3.5. Kaplan-Meir survival.
Adjusted all-cause (A) and CVD (B) mortality HRs (95% CIs) for IFG, IGT, NDM, and KDM compared with NGT according to ethnic group. Adjusted all-cause (A)
Incidence of DM as a function of TyG index (white bars) or TG/HDL-C ratio (black bars). Incidence of DM as a function of TyG index (white bars) or TG/HDL-C.
Venn diagram highlighting the reason(s) for an invalid liver stiffness evaluation (LSE) in the biopsied patients only. 56/153 patients had an invalid LSE.
Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.
Flow diagram of the patient cohort
Prescribers’ responses rating their level of comfort on a scale of 1–5
 (A) Percentage of patients achieving remission or response at week 12 or 24 after initiating ova therapy.  (A) Percentage of patients achieving remission.
The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.
Presentation transcript:

Percentage of total mortality cases from CHD, CVD, and other causes (A). Percentage of total mortality cases from CHD, CVD, and other causes (A). Mortality from CHD and CVD comprised 57.4%. The percentage of mortality cases associated with a high ratio of TGs to HDL-C was 50.6% of cases with CHD, 46.2% of cases with CVD, and 34.5% of cases with other mortality causes. The rate of CHD, CVD, and other-cause mortality for those with high ratio was higher than for those with low TG/HDL-C (B). PY indicates patient-years. Gloria Lena Vega et al. J Investig Med 2014;62:345-349 Copyright © American Federation for Medical Research. All rights reserved.